Search

Your search keyword '"Nichols, William C."' showing total 219 results

Search Constraints

Start Over You searched for: Author "Nichols, William C." Remove constraint Author: "Nichols, William C." Publication Year Range Last 10 years Remove constraint Publication Year Range: Last 10 years
219 results on '"Nichols, William C."'

Search Results

1. Deficiency of the Deubiquitinase UCHL1 Attenuates Pulmonary Arterial Hypertension

2. Metabolomic Profiles Differentiate Scleroderma-PAH From Idiopathic PAH and Correspond With Worsened Functional Capacity

5. Defining the clinical validity of genes reported to cause pulmonary arterial hypertension

6. Genetic Admixture and Survival in Diverse Populations with Pulmonary Arterial Hypertension

7. Novel risk genes and mechanisms implicated by exome sequencing of 2572 individuals with pulmonary arterial hypertension

10. Genetic regulation and targeted reversal of lysosomal dysfunction and inflammatory sterol metabolism in pulmonary arterial hypertension

11. NHLBI-CMREF Workshop Report on Pulmonary Vascular Disease Classification: JACC State-of-the-Art Review

14. Allele-specific control of rodent and human lncRNA KMT2E-AS1 promotes hypoxic endothelial pathology in pulmonary hypertension

15. Pediatric pulmonary hypertension: insulin-like growth factor-binding protein 2 is a novel marker associated with disease severity and survival

16. The relationship between obsessive‐compulsive symptoms and PARKIN genotype: The CORE‐PD study

17. Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis

20. Novel Mutations and Decreased Expression of the Epigenetic Regulator TET2 in Pulmonary Arterial Hypertension

21. SOX17 Deficiency Mediates Pulmonary Hypertension: At the Crossroads of Sex, Metabolism, and Genetics

22. RASA3 is a Candidate Gene in Sickle Cell Disease‐Associated Pulmonary Hypertension and Pulmonary Arterial Hypertension

23. Insulin‐like growth factor binding Protein‐4: A novel indicator of pulmonary arterial hypertension severity and survival

25. Integrative Multiomics to Dissect the Lung Transcriptional Landscape of Pulmonary Arterial Hypertension

26. Integrative Multiomics to Dissect the Lung Transcriptional Landscape of Pulmonary Arterial Hypertension

27. Low‐affinity insulin‐like growth factor binding protein 7 and its association with pulmonary arterial hypertension severity and survival.

28. Rare variants in SOX17 are associated with pulmonary arterial hypertension with congenital heart disease

29. Mining the Plasma Proteome for Insights into the Molecular Pathology of Pulmonary Arterial Hypertension

30. Mendelian randomisation and experimental medicine approaches to IL-6 as a drug target in PAH

31. COL18A1 genotypic associations with endostatin levels and clinical features in pulmonary arterial hypertension: a quantitative trait association study

32. Biomarkers of Pulmonary Hypertension Are Altered in Children with Down Syndrome and Pulmonary Hypertension

33. Parkinson Disease and Subthalamic Nucleus Deep Brain Stimulation: Cognitive Effects inGBAMutation Carriers

34. Hepatoma‐derived growth factor is associated with pulmonary vascular remodeling and PAH disease severity and survival

35. Abstract 12319: 16alpha-Hydroxyestrone Downregulates SOX17 During the Development of Pulmonary Arterial Hypertension

36. Rare variant analysis of 4241 pulmonary arterial hypertension cases from an international consortium implicates FBLN2, PDGFD, and rare de novo variants in PAH

37. Angiostatic Peptide, Endostatin, Predicts Severity in Pediatric Congenital Heart Disease–Associated Pulmonary Hypertension

38. Subthalamic Peak Beta Ratio Is Asymmetric in Glucocerebrosidase Mutation Carriers With Parkinson's Disease: A Pilot Study

39. Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertension

40. The angiostatic peptide endostatin enhances mortality risk prediction in pulmonary arterial hypertension

42. Metabolomic Profiles of Scleroderma-PAH are different than idiopathic PAH and associated with worse clinical outcomes

43. ST2 Is a Biomarker of Pediatric Pulmonary Arterial Hypertension Severity and Clinical Worsening

44. Additional file 1 of Rare variant analysis of 4241 pulmonary arterial hypertension cases from an international consortium implicates FBLN2, PDGFD, and rare de novo variants in PAH

45. Additional file 2 of Rare variant analysis of 4241 pulmonary arterial hypertension cases from an international consortium implicates FBLN2, PDGFD, and rare de novo variants in PAH

46. Cognitive Functioning of Glucocerebrosidase (GBA) Non-manifesting Carriers

47. Bayesian Inference Associates Rare KDR Variants With Specific Phenotypes in Pulmonary Arterial Hypertension

48. Whole Blood RNA Profiles Associated with Pulmonary Arterial Hypertension and Clinical Outcome

49. Reduced transfer coefficient of carbon monoxide in pulmonary arterial hypertension implicates rare protein-truncating variants in KDR

50. United States Pulmonary Hypertension Scientific Registry

Catalog

Books, media, physical & digital resources